Immunic Cash Ratio vs Begin Period Cash Flow Analysis

IMUX Stock

USD 1.38 0.04 2.99%

Immunic financial indicator trend analysis is infinitely more than just investigating Immunic recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunic is a good investment. Please check the relationship between Immunic Cash Ratio and its Begin Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

Cash Ratio vs Begin Period Cash Flow

Cash Ratio vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunic Cash Ratio account and Begin Period Cash Flow. At this time, the significance of the direction appears to have weak relationship.

The correlation between Immunic's Cash Ratio and Begin Period Cash Flow is 0.32. Overlapping area represents the amount of variation of Cash Ratio that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Immunic, assuming nothing else is changed. The correlation between historical values of Immunic's Cash Ratio and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Ratio of Immunic are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Cash Ratio i.e., Immunic's Cash Ratio and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.32

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cash Ratio

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Immunic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.Selling General Administrative is likely to drop to about 14 M in 2024. Issuance Of Capital Stock is likely to drop to about 810.4 K in 2024

	2021	2022	2023	2024 (projected)
Net Interest Income	66K	1.0M	3.1M	3.2M
Interest Income	66K	1.0M	3.1M	3.2M

Net Interest Income Interest Income

Immunic fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Short Term Investments	Non Currrent Assets Other	Common Stock Total Equity	Common Stock	Net Tangible Assets	Retained Earnings Total Equity
Total Assets		0.31	0.21	0.39	0.96	0.21	-0.95	-0.04	0.57	0.96	0.6	0.96	0.41	-0.62	0.55	0.33	-0.53	0.21	0.97	-0.23	-0.48	-0.53	0.28	0.28	0.34	0.05
Short Long Term Debt Total	0.31		0.63	0.69	0.21	-0.04	-0.31	-0.58	0.2	0.34	-0.16	0.37	0.82	-0.22	0.38	0.56	0.05	-0.04	0.39	-0.03	0.06	-0.45	0.56	0.56	0.47	-0.51
Other Current Liab	0.21	0.63		0.92	0.12	0.28	-0.27	-0.6	0.41	0.33	-0.32	0.33	0.74	-0.41	0.06	0.4	-0.07	0.28	0.31	-0.18	-0.38	-0.4	0.59	0.6	0.28	-0.56
Total Current Liabilities	0.39	0.69	0.92		0.27	0.09	-0.34	-0.6	0.39	0.41	0.0	0.4	0.91	-0.46	0.39	0.45	-0.08	0.09	0.42	-0.07	-0.42	-0.56	0.57	0.58	0.31	-0.46
Total Stockholder Equity	0.96	0.21	0.12	0.27		0.28	-0.94	-0.04	0.55	0.93	0.59	0.92	0.26	-0.75	0.51	0.38	-0.73	0.28	0.93	-0.14	-0.6	-0.55	0.33	0.32	0.18	0.03
Property Plant And Equipment Net	0.21	-0.04	0.28	0.09	0.28		-0.43	0.06	0.67	0.42	-0.38	0.41	-0.19	-0.34	-0.09	0.04	-0.35	1.0	0.37	-0.58	-0.32	0.24	0.19	0.19	0.17	-0.11
Net Debt	-0.95	-0.31	-0.27	-0.34	-0.94	-0.43		0.03	-0.68	-0.99	-0.39	-0.99	-0.29	0.63	-0.41	-0.34	0.56	-0.43	-0.98	0.34	0.49	0.44	-0.36	-0.36	-0.36	0.05
Retained Earnings	-0.04	-0.58	-0.6	-0.6	-0.04	0.06	0.03		0.13	-0.07	0.24	-0.07	-0.64	0.4	-0.24	-0.88	0.19	0.06	-0.09	-0.15	0.3	0.64	-0.83	-0.84	0.12	0.86
Accounts Payable	0.57	0.2	0.41	0.39	0.55	0.67	-0.68	0.13		0.69	0.03	0.67	0.21	-0.44	0.19	-0.03	-0.33	0.67	0.65	-0.33	-0.41	-0.18	0.24	0.24	0.3	0.01
Cash	0.96	0.34	0.33	0.41	0.93	0.42	-0.99	-0.07	0.69		0.38	0.99	0.36	-0.64	0.42	0.35	-0.54	0.42	0.99	-0.34	-0.5	-0.47	0.38	0.38	0.36	-0.08
Non Current Assets Total	0.6	-0.16	-0.32	0.0	0.59	-0.38	-0.39	0.24	0.03	0.38		0.35	0.12	-0.27	0.43	0.02	-0.3	-0.38	0.39	0.27	-0.33	-0.43	-0.19	-0.2	-0.03	0.53
Cash And Short Term Investments	0.96	0.37	0.33	0.4	0.92	0.41	-0.99	-0.07	0.67	0.99	0.35		0.37	-0.63	0.43	0.35	-0.53	0.41	1.0	-0.36	-0.44	-0.45	0.37	0.37	0.38	-0.09
Common Stock Shares Outstanding	0.41	0.82	0.74	0.91	0.26	-0.19	-0.29	-0.64	0.21	0.36	0.12	0.37		-0.33	0.52	0.53	0.03	-0.19	0.4	0.03	-0.2	-0.62	0.51	0.52	0.39	-0.43
Non Current Liabilities Total	-0.62	-0.22	-0.41	-0.46	-0.75	-0.34	0.63	0.4	-0.44	-0.64	-0.27	-0.63	-0.33		-0.34	-0.55	0.92	-0.34	-0.63	-0.12	0.87	0.67	-0.56	-0.57	0.2	0.32
Other Current Assets	0.55	0.38	0.06	0.39	0.51	-0.09	-0.41	-0.24	0.19	0.42	0.43	0.43	0.52	-0.34		0.4	-0.22	-0.09	0.51	-0.06	-0.2	-0.42	0.32	0.32	0.23	-0.18
Other Stockholder Equity	0.33	0.56	0.4	0.45	0.38	0.04	-0.34	-0.88	-0.03	0.35	0.02	0.35	0.53	-0.55	0.4		-0.42	0.04	0.38	0.04	-0.39	-0.7	0.86	0.86	0.0	-0.73
Total Liab	-0.53	0.05	-0.07	-0.08	-0.73	-0.35	0.56	0.19	-0.33	-0.54	-0.3	-0.53	0.03	0.92	-0.22	-0.42		-0.35	-0.52	-0.16	0.79	0.51	-0.39	-0.38	0.36	0.16
Property Plant And Equipment Gross	0.21	-0.04	0.28	0.09	0.28	1.0	-0.43	0.06	0.67	0.42	-0.38	0.41	-0.19	-0.34	-0.09	0.04	-0.35		0.37	-0.58	-0.32	0.24	0.19	0.19	0.17	-0.11
Total Current Assets	0.97	0.39	0.31	0.42	0.93	0.37	-0.98	-0.09	0.65	0.99	0.39	1.0	0.4	-0.63	0.51	0.38	-0.52	0.37		-0.35	-0.45	-0.47	0.37	0.38	0.4	-0.09
Short Term Debt	-0.23	-0.03	-0.18	-0.07	-0.14	-0.58	0.34	-0.15	-0.33	-0.34	0.27	-0.36	0.03	-0.12	-0.06	0.04	-0.16	-0.58	-0.35		-0.17	-0.43	0.05	0.06	-0.68	-0.04
Short Term Investments	-0.48	0.06	-0.38	-0.42	-0.6	-0.32	0.49	0.3	-0.41	-0.5	-0.33	-0.44	-0.2	0.87	-0.2	-0.39	0.79	-0.32	-0.45	-0.17		0.59	-0.45	-0.45	0.3	0.18
Non Currrent Assets Other	-0.53	-0.45	-0.4	-0.56	-0.55	0.24	0.44	0.64	-0.18	-0.47	-0.43	-0.45	-0.62	0.67	-0.42	-0.7	0.51	0.24	-0.47	-0.43	0.59		-0.68	-0.69	0.24	0.45
Common Stock Total Equity	0.28	0.56	0.59	0.57	0.33	0.19	-0.36	-0.83	0.24	0.38	-0.19	0.37	0.51	-0.56	0.32	0.86	-0.39	0.19	0.37	0.05	-0.45	-0.68		1.0	-0.08	-0.87
Common Stock	0.28	0.56	0.6	0.58	0.32	0.19	-0.36	-0.84	0.24	0.38	-0.2	0.37	0.52	-0.57	0.32	0.86	-0.38	0.19	0.38	0.06	-0.45	-0.69	1.0		-0.08	-0.87
Net Tangible Assets	0.34	0.47	0.28	0.31	0.18	0.17	-0.36	0.12	0.3	0.36	-0.03	0.38	0.39	0.2	0.23	0.0	0.36	0.17	0.4	-0.68	0.3	0.24	-0.08	-0.08		0.15
Retained Earnings Total Equity	0.05	-0.51	-0.56	-0.46	0.03	-0.11	0.05	0.86	0.01	-0.08	0.53	-0.09	-0.43	0.32	-0.18	-0.73	0.16	-0.11	-0.09	-0.04	0.18	0.45	-0.87	-0.87	0.15

Click cells to compare fundamentals

Immunic Account Relationship Matchups

Immunic fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	66.0M	167.9M	139.1M	127.8M	54.3M	81.3M
Other Current Liab	343K	4.7M	585K	8.2M	18.9M	19.9M
Total Current Liabilities	7.1M	8.4M	11.4M	13.1M	24.7M	26.0M
Total Stockholder Equity	58.4M	158.8M	127.1M	113.7M	28.9M	27.5M
Property Plant And Equipment Net	713K	1.1M	1.1M	1.8M	1.8M	1.4M
Net Debt	(28.8M)	(126.8M)	(86.3M)	(105.2M)	(45.3M)	(47.6M)
Retained Earnings	(59.9M)	(103.9M)	(196.9M)	(317.3M)	(410.9M)	(390.3M)
Accounts Payable	2.4M	3.7M	3.7M	4.3M	5.1M	3.9M
Cash	29.4M	127.5M	86.9M	106.7M	46.7M	64.0M
Non Current Assets Total	33.7M	34.1M	34.1M	1.9M	1.8M	1.7M
Cash And Short Term Investments	29.4M	127.5M	86.9M	116.4M	46.7M	66.0M
Common Stock Shares Outstanding	7.7M	15.7M	23.7M	31.8M	44.3M	46.5M
Liabilities And Stockholders Equity	66.0M	167.9M	139.1M	127.8M	54.3M	81.3M
Non Current Liabilities Total	520K	679K	584K	992K	639.0K	607.0K
Other Current Assets	2.9M	1.2M	18.1M	9.5M	5.2M	4.1M
Other Stockholder Equity	53.7M	266.8M	324.2M	427.9M	436.1M	245.3M
Total Liab	7.6M	9.1M	12.0M	14.1M	25.4M	26.6M
Property Plant And Equipment Gross	713K	1.1M	1.1M	1.8M	1.8M	1.4M
Total Current Assets	32.2M	133.7M	105.0M	125.9M	52.5M	70.8M
Accumulated Other Comprehensive Income	(1.4M)	(4.1M)	(252K)	3.0M	3.8M	3.9M
Non Currrent Assets Other	108K	37K	42K	43K	38.7K	36.8K
Net Tangible Assets	25.4M	125.8M	94.1M	113.7M	130.7M	80.6M
Retained Earnings Total Equity	(59.9M)	(103.9M)	(196.9M)	(317.3M)	(285.6M)	(299.8M)
Capital Surpluse	119.6M	266.8M	324.2M	427.9M	492.1M	326.3M
Non Current Liabilities Other	520K	679K	584K	992K	1.1M	1.2M
Property Plant Equipment	80K	203K	1.1M	294K	264.6K	251.4K
Other Assets	37K	42K	943K	43K	49.5K	47.0K
Net Receivables	408K	1.6M	2.2M	2.7M	703K	1.3M
Net Invested Capital	58.4M	158.8M	127.1M	113.7M	28.9M	27.5M
Net Working Capital	25.2M	125.3M	93.6M	112.8M	27.8M	26.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Immunic offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunic's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunic Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunic Stock:

How To Invest In Immunic

Details

Is Immunic Stock a good investment?

Details

What is Immunic's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.

For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.

You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Immunic Stock analysis

When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.

	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Transaction History View history of all your transactions and understand their impact on performance
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Commodity Directory Find actively traded commodities issued by global exchanges
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Global Correlations Find global opportunities by holding instruments from different markets
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.11)

Return On Assets

(0.68)

Return On Equity

(1.31)

The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunic Cash Ratio vs Begin Period Cash Flow Analysis

Cash Ratio vs Begin Period Cash Flow

Cash Ratio vs Begin Period Cash Flow Correlation Analysis

Correlation Coefficient

Cash Ratio

Begin Period Cash Flow

Immunic fundamental ratios Correlations

Immunic Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunic fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Immunic Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Cash And Short Term Investments	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.97	Total Assets

Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.95	Total Assets
Net Debt	- 0.94	Total Stockholder Equity
Other Stockholder Equity	- 0.88	Retained Earnings